In terms of IDH-mut/1p/19q codeletion and IDH-mut/1p/19q noncodeletion of glioma patients, the outcomes were shown longer PFS than patients with IDH-wild type, but no difference in OS among the subgroups. The gene discussed is IDH2; the disease is central nervous system cancer.